公开(公告)号：US10260097B2

公开(公告)日：2019-04-16

申请号：US14123406

申请日：2012-06-04

申请人： Denis Paul Harkin ,  Fionnuala Patterson ,  Claire Trinder ,  Eamonn J. O'Brien ,  Caroline Michie ,  Charlie Gourley ,  Laura A. Hill ,  Katherine E. Keating ,  Jude O'Donnell ,  Max Bylesjo ,  Steve Deharo ,  Vitali Proutski ,  Richard Kennedy ,  Timothy Davison ,  Andreas Winter ,  Andrena McCavigan

发明人： Denis Paul Harkin ,  Fionnuala Patterson ,  Claire Trinder ,  Eamonn J. O'Brien ,  Caroline Michie ,  Charlie Gourley ,  Laura A. Hill ,  Katherine E. Keating ,  Jude O'Donnell ,  Max Bylesjo ,  Steve Deharo ,  Vitali Proutski ,  Richard Kennedy ,  Timothy Davison ,  Andreas Winter ,  Andrena McCavigan

IPC分类号： C12Q1/6881 ,  C12Q1/6886 ,  G01N33/574

摘要： Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

公开(公告)号：US20140342924A1

公开(公告)日：2014-11-20

申请号：US14123406

申请日：2012-06-04

申请人： Dennis Paul Harkin ,  Fionnuala Patterson ,  Claire Trinder ,  Eamonn J. O'Brien ,  Caroline Michie ,  Charlie Gourley ,  Laura A. Hill ,  Katherine E. Keating ,  Jude O'Donnell ,  Max Bylesjo ,  Steve Deharo ,  Vitali Proutski ,  Richard Kennedy ,  Timothy Davison ,  Andreas Winter ,  Andrena McCavigan

发明人： Dennis Paul Harkin ,  Fionnuala Patterson ,  Claire Trinder ,  Eamonn J. O'Brien ,  Caroline Michie ,  Charlie Gourley ,  Laura A. Hill ,  Katherine E. Keating ,  Jude O'Donnell ,  Max Bylesjo ,  Steve Deharo ,  Vitali Proutski ,  Richard Kennedy ,  Timothy Davison ,  Andreas Winter ,  Andrena McCavigan

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57449 ,  G01N33/57492 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/7014

摘要： Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

摘要翻译： 提供了用于鉴定癌症分子诊断试验的方法和组合物。 该测试鉴定对抗血管生成治疗剂有反应的癌症亚型，并使得能够对该亚型内的患者进行分类。 本发明可用于确定在施用任何抗血管生成剂之前，癌症患者是否具有临床响应性或对治疗方案无反应。 该测试可以用于不同的癌症类型和不同的直接或间接影响血管生成或血管生成信号传导的药物。 此外，本发明可以用作某些癌症类型的预后指标。 特别地，本发明涉及预测标记物的某些组合的用途，其中预测标记的表达与对治疗方案的反应性或非反应性相关。

公开(公告)号：US09670547B2

公开(公告)日：2017-06-06

申请号：US13821404

申请日：2011-09-15

申请人： Jude O'Donnell ,  Max Bylesjo ,  Fionnuala Patterson ,  Steve Deharo ,  Laura A. Hill ,  Katherine E. Keating ,  Timothy Davison ,  Vitali Proutski ,  Denis Paul Harkin ,  Richard Kennedy ,  Nicolas Goffard

发明人： Jude O'Donnell ,  Max Bylesjo ,  Fionnuala Patterson ,  Steve Deharo ,  Laura A. Hill ,  Katherine E. Keating ,  Timothy Davison ,  Vitali Proutski ,  Denis Paul Harkin ,  Richard Kennedy ,  Nicolas Goffard

IPC分类号： C12Q1/68 ,  C40B30/04 ,  G06F19/20 ,  G06F19/24

CPC分类号： C12Q1/6886 ,  A61K33/24 ,  C12Q1/6876 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  C40B30/04 ,  G06F19/00 ,  G06F19/20 ,  G06F19/24 ,  G16H50/30

摘要： Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

公开(公告)号：US20140051591A1

公开(公告)日：2014-02-20

申请号：US13821404

申请日：2011-09-15

申请人： Jude O'Donnell ,  Max Bylesjo ,  Fionnuala Patterson ,  Steve Deharo ,  Laura A. Hills ,  Katherine E. Keating ,  Timothy Davison ,  Vitali Proutski ,  Dennis Paul Harkin ,  Richard Kennedy ,  Nicolas Goffard

发明人： Jude O'Donnell ,  Max Bylesjo ,  Fionnuala Patterson ,  Steve Deharo ,  Laura A. Hills ,  Katherine E. Keating ,  Timothy Davison ,  Vitali Proutski ,  Dennis Paul Harkin ,  Richard Kennedy ,  Nicolas Goffard

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  A61K33/24 ,  C12Q1/6876 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  C40B30/04 ,  G06F19/00 ,  G06F19/20 ,  G06F19/24 ,  G16H50/30

摘要： Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

摘要翻译： 提供了用于鉴定癌症分子诊断试验的方法和组合物。 该测试定义了一种新的DNA损伤修复缺陷型分子亚型，并能够对该亚型中的患者进行分类。 本发明可用于确定在施用任何化学疗法之前，癌症患者是否具有临床响应或对治疗方案无反应。 该测试可以用于不同的癌症类型以及直接或间接影响DNA损伤或修复的不同药物，例如目前使用的许多标准的细胞毒性化学治疗药物。 特别地，本发明涉及预测标记物的某些组合的用途，其中预测标记的表达与对治疗方案的反应性或非反应性相关。